"FDA awards GSK breakthrough status for relapsed osteosarcoma treatment" was originally created and published by ...
The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital ...
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.
Researchers at Mount Sinai and Memorial Sloan Kettering believe they’ve made a breakthrough in a new form of cancer treatment ...
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
This story first appeared in Colorado Newsline. Coloradans will soon be able to take psychedelic mushrooms in a regulated ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
A groundbreaking therapy first introduced by Northwestern University researchers in 2021 has shown promise in regenerating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback